Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary)
- Indications Palmoplantar pustulosis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 01 Dec 2021 Results assessing efficacy and safety of guselkumab through W84, and to explore factors associated with the sustainability of its efficacy in Japanese PPP patients published in the Journal of Dermatology
- 12 Aug 2021 Results of pool analysis from phase 2 (NCT01845987) and phase 3 (NCT02641730) of guselkumab, assessing the longitudinal profile of PPPASI score improvement by guselkumab treatment and clinical implications of guselkumab dose, baseline disease severity and smoking on the treatment effect, by using pharmacokinetic and pharmacodynamic modeling, published in the Journal of Clinical Pharmacology.
- 03 Jul 2019 Results published in the JAMA Dermatology.